Get the latest AbbVie Inc. (ABBV) stock news and headlines to help you in your trading and investing decisions.

3 days ago · AbbVie (NYSE: ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025, before the market opens. AbbVie will host a live webcast of the earnings …

Mar 24, 2025 · AbbVie (ABBV) closed the most recent trading day at $209.17, moving -0.4% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of …

Mar 26, 2025 · AbbVie (NYSE: ABBV) today announced that new data from its early oncology research will be showcased across multiple presentations at the upcoming American …

NORTH CHICAGO, Ill., Feb. 7, 2025 / PRNewswire / -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam …

Nov 30, 2023 · AbbVie will acquire all outstanding ImmunoGen common stock for $31.26 per share in cash. The proposed transaction is subject to customary closing conditions, including …

NORTH CHICAGO, Ill., /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2024. "2024 was a year of significant …

Oct 30, 2024 · AbbVie raised its annual profit forecast after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for third …

Jan 31, 2025 · AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for immunology powerhouses Skyrizi and Rinvoq by $4 billion.

4 days ago · Shares of AbbVie Inc. (NYSE:ABBV - Get Free Report) have received an average rating of "Moderate Buy" from the twenty-five brokerages that are currently covering the …